Infliximab testing available at the uah laboratory
January 13, 2014
Calgary Zone, Central Zone, Edmonton Zone and North Zone
Gastroenterologists, Laboratory Directors and Managers
AHS Laboratory Services – University of Alberta Hospital Laboratory (UAH)
Infliximab Testing Available at the UAH Laboratory
PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE
Infliximab (Remicade) and anti-infliximab antibody measurement (ATI) will be available through the Division of Biochemistry at the University of Alberta Hospital Laboratory in January 2014.
Infliximab levels reported from this enzyme-linked immunosorbent assay (ELISA) method are comparable to the results produced by the Prometheus High Performance Liquid Chromatography (HPLC) method. While the quantitative ATI result will differ, specimens containing antibody should be positive in both methods.
The testing is approved for patients being treated for Inflammatory Bowel Disease
who have a
decreased response to the drug.
ATI will be added to all specimens with an infliximab level < 3.0 µg/mL. If ATI levels are required on other specimens it must be specified.
Ordering will be restricted to Gastroenterology. The Infliximab Level Order form must be
completed by the Gastroenterologist prior to processing the request.
Trough levels < 3.0 µg/mL are sub-therapeutic.
Levels >2 µg/mL indicate the presence of antibodies which will
reduce the availability of infliximab and increase its clearance.
Complete the attached Infliximab Level Order Form. Form must accompany the laboratory requisition and specimen.
Collect 1 SST gel tube prior to the next infusion i.e. a trough level (minimum of 1 mL serum required).
: Centrifuge sample and send two frozen serum aliquots (0.5 mL) to: Biochemistry
WMC 4B2.10, University of Alberta Hospital, 8440 – 112 St, Edmonton AB, T6G 2B7
Inquiries and feedback may be directed to:
Dr. Connie Prosser, Clinical Biochemist, University of Alberta Hospital at: 780-407-8492 or email:
This bulletin has been reviewed and approved by
Dr. Carolyn O’Hara, Medical/Scientific Director and Zone Clinical Department Head, AHS Laboratory Services,
Regional Laboratory Services
Infliximab Level Order Form
Special Investigations - Client Resource
Infliximab Level Order Form
Requesting gastroenterologist must submit a completed form with the laboratory requisition.
Patient Name ________________________
Collection Date _______________ Collection Time _______________ Anti-infliximab Antibody if infliximab > 3.0 µg/ml ________
REASON FOR LEVEL
Date of last infusion (MM/DD/YY): __ __/ __ __/ __ __
Weight of patient at time of collection: __ __ __ kg
DISEASE CHARACTERISTICS and MANAGEMENT
Attach completed form to completed routine requisition
Dietary Considerations in Coumadin® Patients Coumadin® (generic name “warfarin”) acts by impairing the function of Vitamin K. Dietary intake of Vitamin K will counteract the medicinal purpose of Coumadin® Intake of large amounts of Vitamin K can diminish the effect of Coumadin®, permitting the blood to clot. Likewise, if you eat too little vitamin K, it may cause your blood to become t
DATE ISSUED: 22 July 2005 PREPARED BY: SM Peters UPDATED BY: Ursula Potgieter UPDATED : 25 March 2013 MATERIAL SAFETY DATA SHEET NUVAN PROFI 1. COMPANY DETAILS: Address: Tel. Nr.: Emergency Tel Nr.: 083 326 3581 / 082 823 4473 2. PRODUCT IDENTIFICATION: Trade Name: Common Name (ISO): Chemical Name: Simplified formula : Molecular weight: